S100A9 is indispensable for survival of pneumococcal pneumonia in mice
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011493 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Lena Ostermann und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Pneumology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Pneumonia, Pneumococcal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
S100A8/A9 has important immunomodulatory roles in antibacterial defense, but its relevance in focal pneumonia caused by Streptococcus pneumoniae ( S . pneumoniae ) is understudied. We show that S100A9 was significantly increased in BAL fluids of patients with bacterial but not viral pneumonia and correlated with procalcitonin and sequential organ failure assessment scores. Mice deficient in S100A9 exhibited drastically elevated Zn 2+ levels in lungs, which led to bacterial outgrowth and significantly reduced survival. In addition, reduced survival of S100A9 KO mice was characterized by excessive release of neutrophil elastase, which resulted in degradation of opsonophagocytically important collectins surfactant proteins A and D. All of these features were attenuated in S . pneumoniae -challenged chimeric WT→S100A9 KO mice. Similarly, therapy of S . pneumoniae -infected S100A9 KO mice with a mutant S100A8/A9 protein showing increased half-life significantly decreased lung bacterial loads and lung injury. Collectively, S100A9 controls central antibacterial immune mechanisms of the lung with essential relevance to survival of pneumococcal pneumonia. Moreover, S100A9 appears to be a promising biomarker to distinguish patients with bacterial from those with viral pneumonia. Trial registration : Clinical Trials register ( DRKS00000620 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Experimental Pneumology, Hannover Medical School, Hannover, Germany.
- Clinic for Pneumology, Hannover Medical School, Hannover, Germany.
- German Center for Lung Research, Hannover, Germany.
- Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.
- Institute of Clinical Chemistry, Hannover Medical School, Hannover, Germany.
- Labopart Medical Laboratories, Dresden and Chemnitz, Germany.
ORCID-Profile: Ulrich A Maus
Förderung
- Bundesministerium für Bildung und Forschung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Ostermann, L., Seeliger, B., David, S., Flasche, C., Maus, R., Reinboth, M. S., Christmann, M., Neumann, K., Brand, K., Seltmann, S., Bühling, F., Paton, J. C., Roth, J., Vogl, T., Viemann, D., Welte, T., & Maus, U. A. (2023). S100A9 is indispensable for survival of pneumococcal pneumonia in mice. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011493
Vancouver
Ostermann L, Seeliger B, David S, Flasche C, Maus R, Reinboth MS, et al. S100A9 is indispensable for survival of pneumococcal pneumonia in mice. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011493
BibTeX
@article{Ostermann2023,
author = {Ostermann, Lena and Seeliger, Benjamin and David, Sascha and Flasche, Carolin and Maus, Regina and Reinboth, Marieke S and Christmann, Martin and Neumann, Konstantin and Brand, Korbinian and Seltmann, Stephan and Bühling, Frank and Paton, James C and Roth, Johannes and Vogl, Thomas and Viemann, Dorothee and Welte, Tobias and Maus, Ulrich A},
title = {S100A9 is indispensable for survival of pneumococcal pneumonia in mice},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011493}
}
EUVIMED